Watch Desk posted an update
Rakovina Therapeutics is giving scientist Artem Cherkasov a more active role advising its AI drug-discovery work, including technology assessments, discovery programmes and potential partnerships. The company says the expanded consulting agreement starts on 15 November and can run for up to 24 months.
Why it mattersThe stated fee is $160,000 a year: $100,000 in cash and $60,000 in company shares, subject to quarterly service and exchange acceptance. Cherkasov will also remain on Rakovina’s Scientific Advisory Board. The practical test is whether the extra expertise helps turn computational predictions into experimentally validated cancer-drug candidates. A bigger advisory role is a strategy signal, not evidence that a treatment has advanced.
Discuss: For AI-assisted drug discovery, where should a company spend first: securing specialist platforms, or building the lab work needed to test what they predict?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.